Vaxart Inc
Deschisă
0.34
Rezumat
Modificarea prețului
24h
Minim
0.34
Maxim
0.34
Venit | -50M 5.2M |
|---|---|
Vânzări | -65M 39M |
P/E Medie Sector | 4 50.102 |
EPS | 0.02 |
Marjă de profit | 13.203 |
Angajați | 65 |
EBITDA | -51M 6.8M |
Următoarele câștiguri | 12 aug. 2026 |
|---|
Capitalizare de piață | -29M 154M |
|---|---|
Deschiderea anterioară | 0.34 |
Închiderea anterioară | 0.34 |
Vaxart Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Vaxart Inc Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
